Non-steroidal anti-inflammatory drugs (NSAIDs) interfere with the growth of mammary tumours (Lala et al, 1997;Robertson et al, 1998) and prevent distant metastasis (Hubbard et al, 1988;Khoo et al, 1992) in rodents. The epidemiologic evidence for similar effects in women is limited and inconsistent (Isomäki et al, 1978;Friedman and Ury, 1980;Gridley et al, 1993;Thun et al, 1993;Schreinemachers and Everson, 1994;Harris et al, 1995Harris et al, , 1996Egan et al, 1996).To study the effects of NSAID use on breast cancer risk we carried out a nested case-control study, using the records of the Saskatchewan Cancer Agency (SCA) and data collected routinely by the Saskatchewan Prescription Drug Plan (SPDP), which has provided full or partial outpatient drug coverage to the Saskatchewan population since 1975.To study the effects of NSAID use on breast cancer growth and spread we carried out analyses using the drug exposure histories of the cases and attributes of the stage of their tumours at diagnosis, as assessed by the international tumour-lymph node-metastasis (TNM) system (Spiessl et al, 1992). SUBJECTS AND METHODS Study populationsThe source population was the open population of women aged ≥ 35 years, eligible to receive benefits from the SPDP during 1981 to mid-1995 with no history of cancer since 1970 other than nonmelanoma skin cancer or cervical carcinoma in situ.Subjects entered the source population on 1 January 1981, their 35th birthday, or on the date of immigration to Saskatchewan, whichever occurred latest. Subjects left the source population on 30 June 1995, or on the date of diagnosis of breast cancer, death or emigration, whichever occurred first.The SPDP has provided coverage for outpatient prescription drugs for 94% of the Saskatchewan population (1.01 million people in mid-1991; Rawson et al, 1992). Excluded are aboriginals, military personnel, members of the Royal Canadian Mounted Police, and inmates of federal penitentiaries: they are covered by federal agencies. The accuracy of the identifying and recorded prescription information both exceed 99% (Risch and Howe, 1994).The cases were subjects in the source population who were diagnosed with histologically proven invasive female breast cancer and reported to the SCA. Registration of cancer cases was nearly complete (Parkin et al, 1997). To be in our study, cases must have been eligible to benefit from the SPDP for ≥ 5 years before diagnosis. Hereafter, the date of diagnosis will be designated as the 'index date'. Summary We carried out a nested case-control study to measure the rate ratio (RR) for invasive female breast cancer in relation to nonsteroidal anti-inflammatory drug (NSAID) use. The source population consisted of the female beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970. Four controls/case, matched on age and sampling time, were randomly selected. Dispensing rates during successive time periods characterized NSAID exposure. RRs associated with exposure during each period we...
Summary Epidemiological studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce colorectal cancer incidence. We measured the rate ratio for colorectal adenocarcinoma according to dosage and the timing of exposure by means of a case-control study, nested in a non-concurrent cohort linkage study, using the population of beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970 as the source population. Four controls per case, matched on age and gender and alive when the case was diagnosed, were randomly selected. Dispensing rates, calculated over successive time periods, characterized NSAID exposure. We accrued 3844 cases of colon cancer and 1971 cases of rectal cancer. For colon cancer a significant trend towards a decreasing rate ratio was associated with increasing exposure during the 6 months preceding diagnosis (P-trend = 0.002). For both cancers, significant trends were associated with exposure 11-15 years before diagnosis (colon: P-trend = 0.01; rectum: P-trend = 0.0001). At the highest exposure levels the rate ratio for colon cancer was 0.57 (95% confidence interval (CI) 0.36-0.89); for rectal cancer it was 0.26 (95% CI 0.11-0.61). No protection was associated with exposure during other periods. The timing of NSAID use must be considered in planning intervention trials to prevent colorectal cancer. There may be a 10-year delay before any preventive effect will appear.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.